With approximately one third of all current FDA-approved drugs targeting GPCRs, Verily/Sosei ... well as where he thinks AI’s use in drug discovery and development might lead the industry.

Class Biology with Agile AI and Chemistry Automation for Rapid Discovery of Better Molecules for Highly Valuable G Protein-Coupled Receptor (GPCR) TargetsMENLO PARK, Calif., May 21, 2025 (GLOBE ...

OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the ...

Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, ...

Septerna's Novo Nordisk deal secures $195M upfront, with over $2B potential. Read why SEPN is a market opportunity, as it ...

Septerna's GPCR platform shows promise, but execution risks, funding needs, and competition suggest caution. Click here to ...

The deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and other ...

Septerna, Inc. is a biotechnology company pioneering a new era of GPCR drug discovery powered by its proprietary Native Complex Platform™. Its industrial-scale platform aims to unlock the full ...

SOUTH SAN FFRANCISCO, CA, USA and BAGSVAERD, Denmark I May 14, 2025 I Septerna, Inc. (Nasdaq: SEPN) and Novo Nordisk today announced an exclusive global ...

Septerna, Novo Nordisk partner to discover, develop and commercialize oral small molecule medicines for cardiometabolic ...

2,3 According to Novo Nordisk, GPCRs are the largest and most varied group of cell surface receptors, playing key roles in regulating functions across nearly every organ system in the body. They are ...